$Elanco Animal Health (ELAN.US)$ shares gained 7.5% after Stifel upgraded the stock to buy from hold and boosted the price target for the stock, signaling expectations of a 35% rally.
Below are the analysts' ratings on the stock.
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
01/05/2024 | 34.68% | Stifel | $13 → $20 | Upgrades | Hold → Buy |
12/19/2023 | 14.48% | Jefferies | → $17 | Initiates Coverage On | → Buy |
12/15/2023 | 7.74% | Morgan Stanley | → $16 | Upgrades | Equal-Weight → Overweight |
12/07/2023 | -12.46% | Stifel | $12 → $13 | Maintains | Hold |
11/13/2023 | -19.19% | Piper Sandler | $11 → $12 | Maintains | Neutral |
11/08/2023 | 7.74% | Morgan Stanley | $17 → $16 | Maintains | Equal-Weight |
10/30/2023 | -19.19% | Stifel | $13 → $12 | Maintains | Hold |
08/14/2023 | -12.46% | Piper Sandler | $9 → $13 | Maintains | Neutral |
08/09/2023 | -36.03% | Goldman Sachs | $8.5 → $9.5 | Maintains | Sell |
08/08/2023 | -36.03% | Goldman Sachs | $8.5 → $9.5 | Maintains | Sell |
04/26/2023 | -39.39% | Goldman Sachs | $10.5 → $9 | Maintains | Sell |
04/25/2023 | -39.39% | Goldman Sachs | $10.5 → $9 | Maintains | Sell |
04/20/2023 | -5.72% | Barclays | → $14 | Upgrades | Equal-Weight → Overweight |
02/22/2023 | -5.72% | Barclays | $18 → $14 | Maintains | Equal-Weight |
01/30/2023 | 27.95% | Morgan Stanley | $20 → $19 | Maintains | Equal-Weight |
11/15/2022 | 34.68% | Morgan Stanley | $21 → $20 | Maintains | Equal-Weight |
11/14/2022 | 1.01% | Piper Sandler | $21 → $15 | Maintains | Neutral |
11/09/2022 | -19.19% | Goldman Sachs | $19 → $12 | Maintains | Sell |
10/17/2022 | 34.68% | JP Morgan | $24 → $20 | Maintains | Neutral |
10/07/2022 | 41.41% | Morgan Stanley | $22 → $21 | Maintains | Equal-Weight |
09/12/2022 | 21.21% | Barclays | $32 → $18 | Maintains | Equal-Weight |
08/18/2022 | 48.15% | Morgan Stanley | $37 → $22 | Downgrades | Overweight → Equal-Weight |
08/17/2022 | 41.41% | Piper Sandler | $22 → $21 | Maintains | Neutral |
08/16/2022 | — | JP Morgan | Downgrades | Overweight → Neutral | |
07/21/2022 | 27.95% | Goldman Sachs | $32 → $19 | Downgrades | Buy → Sell |
07/18/2022 | 115.49% | JP Morgan | $37 → $32 | Maintains | Overweight |
07/12/2022 | 48.15% | Piper Sandler | → $22 | Initiates Coverage On | → Neutral |
06/24/2022 | 48.15% | Stifel | $30 → $22 | Maintains | Hold |
05/19/2022 | 115.49% | Goldman Sachs | $37 → $32 | Maintains | Buy |
05/17/2022 | 149.16% | Morgan Stanley | $40 → $37 | Maintains | Overweight |
02/28/2022 | 115.49% | Barclays | $30 → $32 | Maintains | Equal-Weight |
11/18/2021 | 169.36% | Morgan Stanley | → $40 | Initiates Coverage On | → Overweight |
10/28/2021 | 128.96% | Stifel | $37 → $34 | Downgrades | Buy → Hold |
05/11/2021 | — | Gabelli & Co. | Upgrades | Hold → Buy | |
05/11/2021 | 95.29% | Barclays | $25 → $29 | Upgrades | Underweight → Equal-Weight |
04/15/2021 | 149.16% | Stifel | → $37 | Initiates Coverage On | → Buy |
03/22/2021 | 115.49% | Gabelli & Co. | → $32 | Downgrades | Buy → Hold |
02/26/2021 | 155.89% | Credit Suisse | $33 → $38 | Upgrades | Neutral → Outperform |
11/24/2020 | 176.09% | Morgan Stanley | $31 → $41 | Maintains | Overweight |
11/23/2020 | 176.09% | Morgan Stanley | $31 → $41 | Maintains | Overweight |
11/17/2020 | 135.69% | Citigroup | $32 → $35 | Maintains | Buy |
08/20/2020 | 108.75% | Morgan Stanley | → $31 | Upgrades | Equal-Weight → Overweight |
08/13/2020 | 81.82% | Credit Suisse | → $27 | Reinstates | → Neutral |
08/04/2020 | 78.45% | Goldman Sachs | → $26.5 | Reinstates | → Buy |
07/27/2020 | 27.95% | Cleveland Research | → $19 | Downgrades | Neutral → Underperform |
07/20/2020 | 88.55% | B of A Securities | $26 → $28 | Maintains | Buy |
05/15/2020 | 81.82% | Citigroup | $35 → $27 | Maintains | Buy |
04/02/2020 | — | Morgan Stanley | Downgrades | Overweight → Equal-Weight | |
01/10/2020 | — | Raymond James | Initiates Coverage On | → Market Perform | |
12/19/2019 | — | B of A Securities | Upgrades | Neutral → Buy | |
11/20/2019 | 88.55% | UBS | $30 → $28 | Maintains | Neutral |
11/07/2019 | 115.49% | Morgan Stanley | $34 → $32 | Upgrades | Equal-Weight → Overweight |
09/23/2019 | 142.42% | Barclays | → $36 | Initiates Coverage On | → Overweight |
08/26/2019 | — | B of A Securities | Downgrades | Buy → Neutral | |
08/15/2019 | 102.02% | UBS | $31 → $30 | Upgrades | Sell → Neutral |
05/23/2019 | — | Guggenheim | Initiates Coverage On | → Neutral | |
05/10/2019 | 135.69% | BMO Capital | $32 → $35 | Maintains | Market Perform |
03/20/2019 | 88.55% | UBS | $29 → $28 | Reinstates | → Sell |
03/18/2019 | — | B of A Securities | Upgrades | Neutral → Buy | |
02/12/2019 | — | William Blair | Initiates Coverage On | → Market Perform | |
01/23/2019 | — | UBS | Initiates Coverage On | → Sell | |
01/15/2019 | 149.16% | Argus Research | → $37 | Initiates Coverage On | → Buy |